Next Treatments
Back to Eczema

aletekitug

TypeInjection StageStopped · Phase 2 Why it stoppedDidn't work well enough · GlaxoSmithKline · Jul 29, 2025“Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified.” (NCT06447506)1 other trial stopped Latest updateJun 16, 2026Phase 2 results posted · Trial stopped early

What stands out

  • Monoclonal antibody
Derived from FDA substance registry · This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: NCT04975438
Percent Change From Baseline (PCFB) in EASI Score at Week 12 in Group 1After 12 weeks

Lower scores mean less severe eczema.

Placebo9 people
33% lower
GSK107080619 people
66% lower
040%80%
33points
more of a drop on average on aletekitug than on placebo.
The sponsor’s 95% confidence range is 15 to 51 points more.
NCT04975438 · Ages 18–75 · Results posted Jul 2024 · This is a summary of trial data for informational purposes only. It is not medical advice.
What is EASI?
  • EASI stands for Eczema Area and Severity Index.
  • EASI scoring system is standardized clinical tool for assessment of extent (area) and severity of atopic dermatitis (AD). Severity of clinical signs of AD (erythema, induration/papulation, excoriation and lichenification) scored separately for each of 4 body regions (head and neck, upper limbs, trunk and lower limbs on 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe.As this trial registered it · NCT04975438 (the full definition is there)
Why this trial?

Of aletekitug’s 3 trials with posted results, NCT04975438 is the only one that compared the drug with placebo on a result this page charts and can be shown first. A trial that stopped early is listed but never shown first.

All 3 aletekitug trials
PostedTrialPhaseAgesPeople
Jun 2026AtDvancePhase 218+79
Jun 2026AtDventurePhase 218–75161
Jul 2024NCT04975438 Shown abovePhase 118–7534

History

Earliest recorded event: Nov 18, 2021. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Jun 16, 2026Phase 2 results posted · Trial stopped earlyLong-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis. Why it stopped: Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified. ClinicalTrials.gov NCT06447506
  • Jun 3, 2026Phase 2 results posted · Trial stopped earlyA Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis Why it stopped: Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified. ClinicalTrials.gov NCT05999799
  • Jul 29, 2025Trial stopped earlyReason: Sponsor decision to early terminate the study following the termination of the parent study (NCT05999799), which met pre-defined futility criterion for efficacy. No safety concerns were identified. ClinicalTrials.gov NCT06447506
  • Jul 23, 2025Trial stopped earlyReason: Sponsor decision to early terminate the study based on the pre-defined futility criterion for efficacy. No safety concerns were identified. ClinicalTrials.gov NCT05999799
  • Jul 23, 2024Phase 1 results postedClinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis ClinicalTrials.gov NCT04975438
  • Dec 28, 2023Phase 1 trial completedA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive ClinicalTrials.gov NCT05590338
  • Jul 12, 2023Phase 1 main data collectedA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive ClinicalTrials.gov NCT05590338
  • Mar 13, 2023Phase 1 trial completedClinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis ClinicalTrials.gov NCT04975438
  • Dec 19, 2022Phase 1 main data collectedClinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis ClinicalTrials.gov NCT04975438
  • Nov 4, 2022Phase 1 trial startedA Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic of GSK1070806 After a Single Intravenous Dose in Healthy Male and Female Caucasian, Chinese and Japanese Participants Aged 18 to 65 Years of Age Inclusive ClinicalTrials.gov NCT05590338
  • Nov 18, 2021Phase 1 trial startedClinical Effect, Safety and Tolerability of GSK1070806 in Atopic Dermatitis ClinicalTrials.gov NCT04975438

Sources

Trials